Evaluation of Treatment with a single (400mg) versus double dose (800mg) of Tocilizumab in Acute Respiratory Distress Syndrome Associated with COVID-19Pneumonia
Background: COVID-19 is a viral infectious caused by novel coronavirus called as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies have shown that the level of IL-6 in the severe infection group was higher than that in the moderate group, suggesting that IL-6 can be used a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rabia Yılmaz
2022-01-01
|
| Series: | Journal of Contemporary Medicine |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/2109894 |